News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Lytix Biopharma as Update on Phase I Progress with Oncopore(TM) for Solid Tumors
May 20, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
OSLO--(BUSINESS WIRE)--The Norwegian pharmaceutical company Lytix Biopharma AS provided an update at the recent BIO conference in Chicago on Phase I clinical trials of OncoporeTM (LTX-315) for the treatment of cancer.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 1
Europe
MORE ON THIS TOPIC
Immunology and inflammation
Nektar’s Rezpeg Differentiates in Atopic Dermatitis With Durable, Deep Responses in Mid-Stage
February 11, 2026
·
2 min read
·
Tristan Manalac
Vaccines
FDA Refuses To Review Moderna’s mRNA Flu Vaccine, Claims Trial Inadequacies
February 11, 2026
·
4 min read
·
Tristan Manalac
Podcast
Weight Loss Drama Compounds on Heels of Novo, Lilly Earnings, Plus Gene Therapy News
February 11, 2026
·
1 min read
·
Jef Akst
Immunology and inflammation
Evommune Soars as Dermatitis Treatment Rivals Dupixent in Mid-Stage Trial
February 10, 2026
·
1 min read
·
Dan Samorodnitsky
